Patents by Inventor Toshihiro Nakashima
Toshihiro Nakashima has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11186630Abstract: A human antibody which comprises a complementarity determining region of an H chain consisting of the amino acid sequence as shown in SEQ ID NOs: 1 to 3 and a complementarity determining region of an L chain consisting of the amino acid sequence as shown in SEQ ID NOs: 4 to 6. The human antibody of the present invention has the activity to specifically bind to transthyretin (TTR) with structural change and the activity to inhibit fibrillization of TTR and is a human antibody suitable for application to human body.Type: GrantFiled: February 6, 2020Date of Patent: November 30, 2021Assignee: KM BIOLOGICS CO., LTD.Inventors: Masaharu Torikai, Akihiko Hosoi, Tomoyo Takeo, Masayo Ueno, Kenji Soejima, Toshihiro Nakashima, Yukio Ando, Hirofumi Jono, Yu Su, Mineyuki Mizuguchi
-
Publication number: 20200181250Abstract: A human antibody which comprises a complementarity determining region of an H chain consisting of the amino acid sequence as shown in SEQ ID NOs: 1 to 3 and a complementarity determining region of an L chain consisting of the amino acid sequence as shown in SEQ ID NOs: 4 to 6. The human antibody of the present invention has the activity to specifically bind to transthyretin (TTR) with structural change and the activity to inhibit fibrillization of TTR and is a human antibody suitable for application to human body.Type: ApplicationFiled: February 6, 2020Publication date: June 11, 2020Applicant: KM Biologics Co., Ltd.Inventors: Masaharu TORIKAI, Akihiko HOSOI, Tomoyo TAKEO, Masayo UENO, Kenji SOEJIMA, Toshihiro NAKASHIMA, Yukio ANDO, Hirofumi JONO, Yu SU, Mineyuki MIZUGUCHI
-
Patent number: 10604562Abstract: A humanized antibody which comprises a complementarity determining region of an H chain consisting of the amino acid sequence as shown in SEQ ID NOs: 1 to 3 and a complementarity determining region of an L chain consisting of the amino acid sequence as shown in SEQ ID NOs: 4 to 6. The humanized antibody of the present invention has the activity to specifically bind to transthyretin (TTR) with structural change and the activity to inhibit fibrillization of TTR and is a humanized antibody suitable for application to human body.Type: GrantFiled: January 23, 2015Date of Patent: March 31, 2020Assignees: KM BIOLOGICS CO., LTD., NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITYInventors: Akihiko Hosoi, Masaharu Torikai, Tomoyo Takeo, Masayo Ueno, Hirofumi Higuchi, Kenji Soejima, Toshihiro Nakashima, Yukio Ando, Hirofumi Jono, Yu Su
-
Patent number: 10597440Abstract: A human antibody which comprises a complementarity determining region of an H chain consisting of the amino acid sequence as shown in SEQ ID NOs: 1 to 3 and a complementarity determining region of an L chain consisting of the amino acid sequence as shown in SEQ ID NOs: 4 to 6. The human antibody of the present invention has the activity to specifically bind to transthyretin (TTR) with structural change and the activity to inhibit fibrillization of TTR and is a human antibody suitable for application to human body.Type: GrantFiled: January 23, 2015Date of Patent: March 24, 2020Assignee: KM BIOLOGICS CO., LTD.Inventors: Masaharu Torikai, Akihiko Hosoi, Tomoyo Takeo, Masayo Ueno, Kenji Soejima, Toshihiro Nakashima, Yukio Ando, Hirofumi Jono, Yu Su, Mineyuki Mizuguchi
-
Patent number: 10570199Abstract: The present invention relates to a human anti-human IL-18 antibody which reacts with human interleukin-18 (human IL-18) and does not react with a K53A variant of human IL-18.Type: GrantFiled: November 18, 2013Date of Patent: February 25, 2020Assignee: KM Biologics Co., Ltd.Inventors: Hiroyuki Shimizu, Miyuki Matsumoto, Kenji Soejima, Masaharu Torikai, Toshihiro Nakashima
-
Patent number: 10487137Abstract: The present invention provides for a method for improving properties of an antibody such as an expression level and stability. A method for obtaining an antibody with an improved expression level and/or stability by modifying human antibody or a humanized antibody, characterized by that at least any one of the amino acid residues at position 8, 12, 15 or 18 (according to Kabat numbering) in a light chain variable region (hereinafter referred to as “VL chain”) of a human antibody or a humanized antibody is substituted with a different amino acid other than proline or cysteine, and a human antibody or a humanized antibody or a human antibody fragment or a humanized antibody fragment with an improved expression level and/or stability which are obtained by said method.Type: GrantFiled: December 11, 2017Date of Patent: November 26, 2019Assignee: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTEInventors: Masaharu Torikai, Toshihiro Nakashima
-
Publication number: 20190077858Abstract: The present invention relates to a human anti-human IL-18 antibody which reacts with human interleukin-18 (human IL-18) and does not react with a K53A variant of human IL-18.Type: ApplicationFiled: November 18, 2013Publication date: March 14, 2019Inventors: Hiroyuki Shimizu, Miyuki Matsumoto, Kenji Soejima, Masaharu Torikai, Toshihiro Nakashima
-
Publication number: 20180118813Abstract: The present invention provides for a method for improving properties of an antibody such as an expression level and stability. A method for obtaining an antibody with an improved expression level and/or stability by modifying human antibody or a humanized antibody, characterized by that at least any one of the amino acid residues at position 8, 12, 15 or 18 (according to Kabat numbering) in a light chain variable region (hereinafter referred to as “VL chain”) of a human antibody or a humanized antibody is substituted with a different amino acid other than proline or cysteine, and a human antibody or a humanized antibody or a human antibody fragment or a humanized antibody fragment with an improved expression level and/or stability which are obtained by said method.Type: ApplicationFiled: December 11, 2017Publication date: May 3, 2018Inventors: Masaharu TORIKAI, Toshihiro NAKASHIMA
-
Patent number: 9873730Abstract: The present invention provides for a method for improving properties of an antibody such as an expression level and stability. A method for obtaining an antibody with an improved expression level and/or stability by modifying a human antibody or a humanized antibody, characterized by that at least any one of the amino acid residues at position 8, 12, 15 or 18 (according to Kabat numbering) in a light chain variable region (hereinafter referred to as “VL chain”) of a human antibody or a humanized antibody is substituted with a different amino acid other than proline or cysteine, and a human antibody or a humanized antibody or a human antibody fragment or a humanized antibody fragment with an improved expression level and/or stability which are obtained by said method.Type: GrantFiled: February 7, 2006Date of Patent: January 23, 2018Assignee: THE CHEMO-SERO-THERAPEUTIC RESERACH INSTITUTEInventors: Masaharu Torikai, Toshihiro Nakashima
-
Publication number: 20160347832Abstract: A humanized antibody which comprises a complementarity determining region of an H chain consisting of the amino acid sequence as shown in SEQ ID NOs: 1 to 3 and a complementarity determining region of an L chain consisting of the amino acid sequence as shown in SEQ ID NOs: 4 to 6. The humanized antibody of the present invention has the activity to specifically bind to transthyretin (TTR) with structural change and the activity to inhibit fibrillization of TTR and is a humanized antibody suitable for application to human body.Type: ApplicationFiled: January 23, 2015Publication date: December 1, 2016Applicants: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE, NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSIT YInventors: Akihiko HOSOI, Masaharu TORIKAI, Tomoyo TAKEO, Masayo UENO, Hirofumi HIGUCHI, Kenji SOEJIMA, Toshihiro NAKASHIMA, Yukio ANDO, Hirofumi JONO, Yu SU
-
Publication number: 20160340419Abstract: A human antibody which comprises a complementarity determining region of an H chain consisting of the amino acid sequence as shown in SEQ ID NOs: 1 to 3 and a complementarity determining region of an L chain consisting of the amino acid sequence as shown in SEQ ID NOs: 4 to 6. The human antibody of the present invention has the activity to specifically bind to transthyretin (TTR) with structural change and the activity to inhibit fibrillization of TTR and is a human antibody suitable for application to human body.Type: ApplicationFiled: January 23, 2015Publication date: November 24, 2016Applicant: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTEInventors: Masaharu TORIKAI, Akihiko HOSOI, Tomoyo TAKEO, Masayo UENO, Kenji SOEJIMA, Toshihiro NAKASHIMA, Yukio ANDO, Hirofumi JONO, Yu SU, Mineyuki MIZUGUCHI
-
Patent number: 8715655Abstract: The present invention provides a human anti-?9 integrin antibody or an antibody fragment which specifically recognize human ?9 integrin and mouse ?9 integrin, inhibit interaction with their ligands, particularly, the antibody or antibody fragment which recognize loop regions of human and mouse ?9 integrins, a gene encoding the antibody or antibody fragment, a recombinant expression vector containing the gene, a transformant harboring the gene, production method of human anti-?9 integrin antibody or antibody fragment using the transformant, and an agent for the prophylaxis or treatment of rheumatoid arthritis which contains the antibody or antibody fragment.Type: GrantFiled: December 26, 2008Date of Patent: May 6, 2014Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research InstituteInventors: Masaharu Torikai, Daisuke Ishikawa, Toshihiro Nakashima, Hirofumi Higuchi, Fumihiko Sakai, Nobuchika Yamamoto, Hirotada Fujita, Katsunari Taguchi
-
Patent number: 8603476Abstract: The present invention provides a humanized anti-human ?9 integrin antibody having improved activity and/or property as compared to a donor mouse anti-human ?9 integrin antibody, namely, a humanized anti-human ?9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:11 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:17, a humanized anti-human ?9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:13 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:17, a humanized anti-human ?9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:15 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:9, and a means for the prophylaxis or treatment of various diseases involving human ?9 integrin in the pathogenesis, whichType: GrantFiled: January 9, 2009Date of Patent: December 10, 2013Assignee: Astellas Pharma Inc.Inventors: Kenji Uehara, Hirofumi Higuchi, Toshihiro Nakashima, Daisuke Ishikawa, Nobuchika Yamamoto, Hirotada Fujita, Fumihiko Sakai
-
Patent number: D676887Type: GrantFiled: October 20, 2011Date of Patent: February 26, 2013Assignee: Panasonic CorporationInventors: Toshihiro Nakashima, Yasuki Yamakawa
-
Patent number: D676900Type: GrantFiled: March 27, 2012Date of Patent: February 26, 2013Assignee: Panasonic CorporationInventors: Akio Ohno, Toshihiro Nakashima, Yasuki Yamakawa, Takayuki Takahashi, Kenzo Horie
-
Patent number: D685835Type: GrantFiled: October 19, 2012Date of Patent: July 9, 2013Assignee: Panasonic CorporationInventor: Toshihiro Nakashima
-
Patent number: D707743Type: GrantFiled: March 27, 2013Date of Patent: June 24, 2014Assignee: Panasonic CorporationInventor: Toshihiro Nakashima
-
Patent number: D712875Type: GrantFiled: September 26, 2013Date of Patent: September 9, 2014Assignee: Panasonic CorporationInventors: Takehito Katori, Toshihiro Nakashima
-
Patent number: D727999Type: GrantFiled: April 25, 2014Date of Patent: April 28, 2015Assignee: Panasonic Intellectual Property Management Co., Ltd.Inventors: Keiji Yuyama, Takashi Tsukahara, Toshihiro Nakashima
-
Patent number: D740792Type: GrantFiled: September 17, 2014Date of Patent: October 13, 2015Assignee: Panasonic Intellectual Property Management Co., Ltd.Inventors: Takeshi Jobetto, Toshihiro Nakashima